Oxford-AstraZeneca Covid vaccine error: What is the way forward for Covishield in India

Health Tips


Oxford AstraZeneca vaccine, Oxford AstraZeneca vaccine update, Oxford AstraZeneca vaccine efficacy, Oxford AstraZeneca covid 19 vaccine, Oxford AstraZeneca vaccine India, Oxford AstraZeneca covid vaccine, Oxford AstraZeneca vaccine trial,There could be two potential reasons behind this mistake committed by the Oxford-AstraZeneca.Oxford-AstraZeneca’s Covid-19 vaccine candidate AZD1222 showed an efficacy rate up to 90 per cent for half dose in November. However, later it was revealed that the positive findings came out due to a mistake. In this article we are looking into why does the mistake matter and what needs to be done now.

Oxford-AstraZeneca Covid-19 vaccine’s efficacy results were based on around 3,000 volunteers who were not supposed to be inoculated with a lower dose of the vaccine. The Oxford in a statement said the doses administered to a batch of volunteers for the phase 3 human trials were overestimated.

There could be two potential reasons behind this mistake committed by the Oxford-AstraZeneca. One there could be haste in completing the human trial. Secondly, competition among pharma firms trying to attract the vaccine market at the earliest, according to an Indian Express report.

The human trials phases are integral and pivotal parts of Coronavirus vaccine development. These phases are absolutely crucial as these phases determine the dosage, safety, and efficacy based on which any candidate gets approval for usage. Protocols and norms that act as guidance remain uniform across all volunteers. Protocol deviations are quite common. But it is a sign to stop and assess the situation. Hence data monitoring is absolutely crucial, the Indian Express report says.

However, India has a relief given the efficacy data is based on the results of UK trials. However, this error underlines the need for greater transparency even for Indian companies that have been conducting trials. Apart from this Regulators will need to review the data more critically. Serum Institue of India, which is conducting human trials of Covishield, must use the available data to chalk down a protocol for additional studies to test the Coronavirus vaccine for appropriate dosage of the Covid-19 vaccine candidate, the Indian Express report says.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.





Source link